Axim Biotechnologies Inc (OTCMKTS: AXIM) is at the helm of affairs. The group recently announced that it had included Dr. Laura Periman in its Medical Advisory Board.
Dr. Periman is a specialist in ocular surface disease and dry eye disease (DED)
With three decades’ experience in medicine, Dr. Periman has spent the last 20 years in clinical practice, besides specializing in ocular surface disease and dry eye disease (DED). At present, she is appointed as Founder and Director of Dry Eye Services and Clinical Research of the Periman Eye Institute, based out of Seattle. In the past, she has worked as principal investigator in ophthalmic clinical research, primarily specializing in treating DED, IPL procedures, and radiofrequency. In addition, Dr. Periman is academically inclined as she is an international lecturer. To her credit, she has reviewed and edited research papers for several medical journals. Furthermore, she has served as a consultant for various ophthalmic pharmaceutical and medical device companies on the corporate front.
With the new addition, Axim Biotechnologies Inc is targeting growth
The Chief Executive Officer of Axim Biotechnologies Inc, John W. Huemoeller II, went on record and stated that the company is targeting to grow from strength to strength with the new addition. Huemoeller II expressed joy in having a world-class DED expert included in the group’s Medical Advisory Board. He stated that Dr. Periman dons many hats as she has a sea of experience as a clinician, investigator, consultant, researcher, editor, and reviewer. The CEO of the group added that the wealth of knowledge that Dr. Periman brings with her could be used to commercialize the company’s ophthalmic diagnostic lab tests besides strengthening the group’s ophthalmic division.
The focus is on treating dry eyes disease as prevalence is high
If numbers are to be believed, the prevalence of dry eyes disease is high, both in the U.S. and across the world. According to the recent data, around 26 million people suffer from this condition in the U.S. alone, and another 300 million individuals are victims of this disease across the globe. Thus, it calls for immediate attention. The fact that this disease affects the young and old, male and female, is a cause of worry.
CytoDyn Inc (OTCMKTS: CYDY) Announces Study to Investigate Leronlimab for Triple-negative Breast Cancer Treatment
Post Views: 18 CytoDyn Inc (OTCMKTS: CYDY) has announced that there will be a study on the drug leronlimab and...
Curaleaf Holdings Inc (OTCMKTS: CURLF) Completes Acquisition of Los Sueños Farms
Post Views: 38 Curaleaf Holdings Inc (OTCMKTS: CURLF) has completed the acquisition of the most enormous outdoor grow in Colorado,...
BAE SYSTEMS ADR (OTCMKTS: BAESY) and Keep Scotland Beautiful Launch Cleaning Hub in Govan
Post Views: 14 BAE SYSTEMS ADR (OTCMKTS: BAESY), a designer, developer and manufacturer of aerospace systems used in space, land,...
Charlotte’s Web Holdings Inc (OTCMKTS: CWBHF) Announces it Will Expand Distribution Following Passing of Assembly Bill 45
Post Views: 10 Charlotte’s Web Holdings Inc (OTCMKTS: CWBHF) has announced that it will expand product distribution in California following...
BAE Systems Inc. (OTCMKTS: BAESY) Granted five-year $68.5 Million Air Traffic Control Contract
Post Views: 12 BAE Systems Inc. (OTCMKTS: BAESY) has been picked for a 5-year $68.5M indefinite-quantity, indefinite-delivery contract enabling it...
CytoDyn Inc (OTCMKTS: CYDY) Announces Appointments of New Chief Operating Officer and Senior Executive Vice President
Post Views: 30 CytoDyn Inc (OTCMKTS: CYDY) has announced that it has appointed Nitya Ray, Ph.D., to act as its...